Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.45 |
| ▸ | GNPAT | O15228 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.42 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30731561 | 1.00 | FOLH1 (0.49) | FOLH1GSRDPP8DPP9DPP7 | |
| SCHEMBL31078367 | 1.00 | FOLH1 (0.49) | FOLH1GSRDPP8DPP9DPP7 | |
| SCHEMBL31078832 | 1.00 | FOLH1 (0.49) | FOLH1GSRDPP8DPP9DPP7 | |
| SCHEMBL31078257 | 1.00 | FOLH1 (0.49) | FOLH1GSRDPP8DPP9DPP7 | |
| SCHEMBL31078363 | 1.00 | FOLH1 (0.49) | FOLH1GSRDPP8DPP9DPP7 | |
| SCHEMBL31078270 | 1.00 | FOLH1 (0.49) | FOLH1GSRDPP8DPP9DPP7 | |
| SCHEMBL31078174 | 1.00 | FOLH1 (0.49) | FOLH1GSRDPP8DPP9DPP7 | |
| SCHEMBL31078294 | 1.00 | FOLH1 (0.49) | FOLH1GSRDPP8DPP9DPP7 | |
| SCHEMBL31078326 | 1.00 | FOLH1 (0.49) | FOLH1GSRDPP8DPP9DPP7 | |
| SCHEMBL30439697 | 1.00 | FOLH1 (0.49) | FOLH1GSRDPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103488-A1 | ACTIVATING AGENTS | INTERK PEPTIDE THERAPEUTICS LIMITED (AU) | 2026-04-16 | — | — | US | disclosed |
| US-12134663-B2 | Cationic peptides for activating Lck | INTERK PEPTIDE THERAPEUTICS LIMITED (AU) | 2024-11-05 | — | — | US | disclosed |
| CN-118698507-A | Preparation method of phospholipid affinity monolithic column and application of monolithic column | 无锡萃纯生物材料科技有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-118638745-A | Method for purifying lentivirus | 无锡萃纯生物材料科技有限公司 | 2024-09-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12134663-B2 | Cationic peptides for activating Lck | LCK, CD69, NFATC1 | FOLH1 2253/4885GSR 4513/4885DPP8 1141/4885 |
| US-20260103488-A1 | ACTIVATING AGENTS | LCK, LTK, CD14 | FOLH1 2942/4885GSR 4221/4885DPP8 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.